NewAmsterdam Pharma Company N.V. Warrant closed at $11.40 on Sep 24, down 0.78%, within 0.3% of its lowest close since Nov 23. Volume of 1.0K shares was 0.29× its 20-day average (below normal).
Split-adjusted performance: -31.0% over one month.
In the quarter ended Jun 30, 2026, revenue was $3.70M, down 80.7% from a year earlier, with a net margin of -1732.9%.
Short interest was 41 shares at the Sep 15 settlement (1.0 days to cover).
No reported quarters with price history yet.
Percentile among 423 companies (100 = best)
Industry medians: 6-month return −2.9%, revenue growth +6.4%, net margin −41.2%, P/E 16.2×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| NAMSWNewAmsterdam Pharma Company N.V. Warrant | $11.40 | −0.78% | — | −80.7% | −1732.9% | — | $52.4M | |
| MDCXWMedicus Pharma Ltd. Warrant | $0.3100 | −12.68% | −44.7% | — | — | — | $305.5K | Compare |
| BFRGWBullfrog AI Holdings, Inc. Warrants | $0.1535 | −19.21% | −9.7% | +547.6% | −636.8% | — | $202.3K | Compare |
| SBFMWSunshine Biopharma Inc. warrant | $0.0540 | +74.19% | −61.4% | −1.6% | −16.9% | — | $165.4K | Compare |
| BFRIWBiofrontera Inc. Warrants | $0.0135 | −32.50% | −66.5% | +32.9% | −5.0% | — | $20.1K | Compare |
| ASBPWAspire-Lakewood Holdings, Inc. Warrant | $0.0133 | −32.83% | −9.5% | — | −2009.6% | — | $159.32 | Compare |
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
